Related Experiment Video

Updated: Oct 12, 2026

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

[Current status in the prevention of Mycobacterium avium complex infections in patients with HIV infection]

T Doco-Lecompte1, F Brel, T May

  • 1Service de Maladies Infectieuses et Tropicales, Hôpitaux de Brabois, Vandoeuvre.

Annales De Medecine Interne
|January 1, 1997
PubMed

Insights

Preventing Mycobacterium avium complex (MAC) infections in AIDS patients requires careful consideration of primary prevention with rifabutin or macrolides. Relapse prevention necessitates prolonged combination therapy, posing management challenges with other treatments.

Area of Science:

  • Infectious Diseases
  • Immunology
  • HIV/AIDS Research

Context:

  • Mycobacterium avium complex (MAC) infections are a significant concern in patients with Acquired Immunodeficiency Syndrome (AIDS).
  • These infections contribute to mortality, particularly in individuals with severe immunodeficiency.
  • The increasing prevalence necessitates a review of effective prevention strategies.

Purpose:

  • To review published studies on the prevention of Mycobacterium avium complex (MAC) infections in patients with AIDS.
  • To evaluate the efficacy and management challenges of prophylactic treatments for MAC.

Summary:

  • Primary prevention of MAC infections can be achieved with rifabutin and newer macrolides like clarithromycin and azithromycin.
  • These agents may fail and present challenges when co-administered with antiretroviral treatments, especially protease inhibitors.
  • Relapse prevention requires prolonged combination therapy, often with a macrolide plus rifabutin or ethambutol, which also complicates management.

Impact:

  • Highlights the efficacy of specific drugs for MAC prevention in immunocompromised individuals.
  • Underscores the complex drug-drug interactions and management difficulties in co-infected patients.
  • Informs clinical practice regarding the optimal use and limitations of current MAC prophylaxis and treatment regimens.

More Related Videos

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Intradermal Inoculation of Mycobacterium avium in the Mouse Ear09:20

Intradermal Inoculation of Mycobacterium avium in the Mouse Ear

Published on: July 3, 2025

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...